India approves Oxford/AstraZeneca vaccine and local jab
3 January 2021, 09:24
The country aims to vaccinate 300 million people by August.
India has given emergency approval to the Oxford University and AstraZeneca vaccine as well as a jab developed in the country to stem the coronavirus pandemic.
Drugs Controller General doctor Venugopal G Somani said that both vaccines will be administered in two dosages.
The country’s initial immunisation plan aims to vaccinate 300 million people — health care workers, front-line staff including police and those considered vulnerable due to their age or other diseases — by August 2021.
A decisive turning point to strengthen a spirited fight!
DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation.
Congratulations India.
Congratulations to our hardworking scientists and innovators.
— Narendra Modi (@narendramodi) January 3, 2021
India’s drug regulator has approved the vaccine & with #UKaid support to COVAX, India will produce 1 billion+ doses for developing countries to keep people safe. Thanks to the expertise at @UniofOxford & @AstraZeneca , we’re now one step close to ending #COVID19 everywhere.
— Dominic Raab (@DominicRaab) January 3, 2021
The Serum Institute of India, the world’s largest vaccine manufacturing company, has been contracted by AstraZeneca to make a billion doses for developing nations, including India.
On Friday, Britain became the first to approve the shot.
The other vaccine known as COVAXIN is developed by Bharat Biotech in collaboration with government agencies and is based on an inactivated form of the coronavirus.
The company has completed only two of three trial phases and the third, which tests for efficacy, began testing in mid-November.
Early clinical studies showed that the vaccine does not have any serious side effects and produces antibodies for Covid-19.
India, with nearly 1.4 billion people, is the second-worst affected by the coronavirus after the US, with over 10.3 million confirmed cases and 149,435 deaths, though its rate of infection has come down significantly from a mid-September peak.
An application for a vaccine made by Pfizer is still being reviewed.
